Amy S Joehlin-Price1, Carmen M Perrino2, Julie Stephens3, Floor J Backes4, Paul J Goodfellow4, David E Cohn4, Adrian A Suarez5. 1. Department of Pathology, The Ohio State University College of Medicine, Columbus, OH, USA. 2. Department of Pathology and Immunology, Washington University in Saint Louis, Saint Louis, MO, USA. 3. Center of Biostatistics, The Ohio State University, Columbus, OH, USA. 4. Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, USA. 5. Department of Pathology, The Ohio State University College of Medicine, Columbus, OH, USA. Electronic address: Adrian.Suarez@osumc.edu.
Abstract
OBJECTIVE: Links between obesity, with its attendant estrogen abnormalities, and the endometrial carcinoma (EC) DNA Mismatch Repair Protein (MMR) system have recently been proposed. We investigated relationships between body mass index (BMI) and clinicopathological correlates including MMR expression in a large single institution EC cohort. METHODS: Clinical and pathological databases from 2007 to 2012 were used to identify consecutive hysterectomy specimens with EC. Univariate and multivariate analyses were used to explore relationships between BMI, age, stage, tumor type and immunohistochemical results for MLH1, PMS2, MSH2 and MSH6. RESULTS: 1049 EC were identified. Overall, BMI was higher amongst women with normal MMR (p=0.002). However, when stratified by age and specific MMR, statistically significant differences localized exclusively to women <50years old with loss of MSH2 and/or MSH6 (p=0.003 and p=0.005 respectively). Higher BMI correlated with endometrioid FIGO 1 and 2 tumors (p<0.001) and with stage 1a (p<0.001). Conversely, MMR abnormalities did not show significant associations with stage (p=0.302) or histologic grade (p=0.097). CONCLUSIONS: BMI showed statistically significant associations with MMR expression, tumor grade and stage amongst 1049 consecutive EC. Obesity correlates with lower grade and stage EC. A link between BMI and maintenance of the MMR system is not supported by our data because the only statistically significant association occurred in women <50years old with MSH2 and/or MSH6 abnormalities where Lynch syndrome related cases are expected to cluster.
OBJECTIVE: Links between obesity, with its attendant estrogen abnormalities, and the endometrial carcinoma (EC) DNA Mismatch Repair Protein (MMR) system have recently been proposed. We investigated relationships between body mass index (BMI) and clinicopathological correlates including MMR expression in a large single institution EC cohort. METHODS: Clinical and pathological databases from 2007 to 2012 were used to identify consecutive hysterectomy specimens with EC. Univariate and multivariate analyses were used to explore relationships between BMI, age, stage, tumor type and immunohistochemical results for MLH1, PMS2, MSH2 and MSH6. RESULTS: 1049 EC were identified. Overall, BMI was higher amongst women with normal MMR (p=0.002). However, when stratified by age and specific MMR, statistically significant differences localized exclusively to women <50years old with loss of MSH2 and/or MSH6 (p=0.003 and p=0.005 respectively). Higher BMI correlated with endometrioid FIGO 1 and 2 tumors (p<0.001) and with stage 1a (p<0.001). Conversely, MMR abnormalities did not show significant associations with stage (p=0.302) or histologic grade (p=0.097). CONCLUSIONS: BMI showed statistically significant associations with MMR expression, tumor grade and stage amongst 1049 consecutive EC. Obesity correlates with lower grade and stage EC. A link between BMI and maintenance of the MMR system is not supported by our data because the only statistically significant association occurred in women <50years old with MSH2 and/or MSH6 abnormalities where Lynch syndrome related cases are expected to cluster.
Authors: B Anderson; J P Connor; J I Andrews; C S Davis; R E Buller; J I Sorosky; J A Benda Journal: Am J Obstet Gynecol Date: 1996-04 Impact factor: 8.661
Authors: S B Simpkins; T Bocker; E M Swisher; D G Mutch; D J Gersell; A J Kovatich; J P Palazzo; R Fishel; P J Goodfellow Journal: Hum Mol Genet Date: 1999-04 Impact factor: 6.150
Authors: H Nakagawa; G J Nuovo; E E Zervos; E W Martin; R Salovaara; L A Aaltonen; A de la Chapelle Journal: Cancer Res Date: 2001-10-01 Impact factor: 12.701
Authors: H Katabuchi; B van Rees; A R Lambers; B M Ronnett; M S Blazes; F S Leach; K R Cho; L Hedrick Journal: Cancer Res Date: 1995-12-01 Impact factor: 12.701
Authors: Seyedeh Ghazaleh Dashti; Rowena Chau; Driss Ait Ouakrim; Daniel D Buchanan; Mark Clendenning; Joanne P Young; Ingrid M Winship; Julie Arnold; Dennis J Ahnen; Robert W Haile; Graham Casey; Steven Gallinger; Stephen N Thibodeau; Noralane M Lindor; Loïc Le Marchand; Polly A Newcomb; John D Potter; John A Baron; John L Hopper; Mark A Jenkins; Aung Ko Win Journal: JAMA Date: 2015-07-07 Impact factor: 56.272
Authors: Neil A J Ryan; Niall J Davison; Katherine Payne; Anne Cole; D Gareth Evans; Emma J Crosbie Journal: Front Oncol Date: 2019-02-26 Impact factor: 6.244
Authors: Neil A J Ryan; Raymond McMahon; Simon Tobi; Tristan Snowsill; Shona Esquibel; Andrew J Wallace; Sancha Bunstone; Naomi Bowers; Ioana E Mosneag; Sarah J Kitson; Helena O'Flynn; Neal C Ramchander; Vanitha N Sivalingam; Ian M Frayling; James Bolton; Rhona J McVey; D Gareth Evans; Emma J Crosbie Journal: PLoS Med Date: 2020-09-17 Impact factor: 11.069
Authors: Christoph Fraune; Eike Burandt; Ronald Simon; Claudia Hube-Magg; Georgia Makrypidi-Fraune; Martina Kluth; Franziska Büscheck; Doris Höflmayer; Niclas Ch Blessin; Tim Mandelkow; Wenchao Li; Daniel Perez; Jakob R Izbicki; Waldemar Wilczak; Guido Sauter; Jörg Schrader; Michael Neipp; Hamid Mofid; Thies Daniels; Christoph Isbert; Till S Clauditz; Stefan Steurer Journal: Ann Surg Oncol Date: 2020-02-27 Impact factor: 4.339